On Jun. 11, 2020, Moderna announcedprogress on late-stage development of mRNA-1273, the Companyﾒs mRNA vaccine candidate against COVID-19. Moderna has finalized the Phase 3 study protocol based on feedback from the U.S. FDA. The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the U.S.